HLA-Independent TCR-T Cell Therapy

The human leukocyte antigen (HLA)-independent TCR-T cell therapy is an innovative immunotherapy that involves genetically modifying a patient's own T cells to express specific T cell receptors (TCRs). These engineered T cells are able to directly recognize and eliminate cancer cells or diseased cells without relying on conventional HLA matching. This breakthrough overcomes the HLA restrictions associated with traditional TCR-T therapies, enabling treatment for a broader patient population-particularly those who are unable to benefit from conventional TCR-T therapy due to HLA limitations.

Therapeutic Process

1) T Cell Collection

Extracting the patient's own T cells from their blood.

2) Genetic Modification

Introducing highly specific, HLA-independent TCRs into T cells via viral or non-viral vectors.

3) Cell Expansion

Expanding the genetically engineered T cells ex vivo to ensure a sufficient number of cells for therapeutic use.

4) Cell Infusion

Enabling the modified T cells to actively recognize target antigens and eliminate diseased cells within the patient's body.

Therapeutic Advantages

• No HLA Matching Required: Expanding patient coverage and reduces screening limitations.
• High Specificity: Customized TCRs can precisely identify tumor-associated antigens or viral antigens, minimizing damage to normal cells.
• Enhanced Efficacy: T cells expanded in vitro and then reinfused have high activity and can continuously attack diseased cells.
• Personalized Treatment: Personalized treatment targeting the patient's specific tumor antigens.

Fig.1 HLA and cancer immunotherapy. (Wang et al., 2020).

Potential Therapeutic Indications

Preliminary clinical trials of super-potent HLA-independent TCR-T cell therapy targeting NY-ESO-1/MAGE-A4/PRAME/ WT1 in patients with relapsed/refractory multiple myeloma have shown excellent efficacy.

• Multi-Target Hi-TCR-T for Hepatocellular Carcinoma